DelveInsight’s “Complicated Intra-Abdominal Infections – Market Insight, Epidemiology, And Market Forecast – 2032″ report offers an in-depth understanding of the Complicated Intra-Abdominal Infections, historical and forecasted epidemiology as well as the Complicated Intra-Abdominal Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Some of the key facts of the Complicated Intra-Abdominal Infections Market Report:
• According to IDSA (2024), complicated intra-abdominal infections (cIAI) are commonly encountered in clinical practice, with appendicitis alone affecting approximately 670,000 patients annually worldwide.
• A study by Labricciosa et al. (2018) recorded a total of 4,040 cases of cIAI, with 92.1% classified as community-acquired (CA-cIAI) and 7.9% as hospital-acquired (HA-cIAI).
• In February 2025, the FDA approved a fixed-dose intravenous combination of aztreonam and avibactam, along with metronidazole (Metrogel; Galderma Labs), for adults aged 18 and older with limited treatment options for complicated intra-abdominal infections (cIAI). This approval covers infections caused by Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
• In February 2025, AbbVie announced that the FDA had approved Emblaveo (aztreonam and avibactam) in combination with metronidazole for adults with complicated intra-abdominal infections (cIAI) and limited treatment options.
• Key companies in the cIAI market include MerLion Pharmaceuticals, AiCuris, Novartis, Allecra, AbbVie, AstraZeneca, Pfizer, Shionogi, Iterum Therapeutics, Nosopharm, and others.
To Know in detail about the Complicated Intra-Abdominal Infections market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Complicated Intra-Abdominal Infections Market Forecast
Complicated Intra-Abdominal Infections OverviewComplicated Intra-Abdominal Infections (cIAIs) are severe infections that extend beyond the organ of origin into the peritoneal cavity, often leading to abscess formation, peritonitis, and sepsis. These infections are commonly caused by polymicrobial pathogens, including Gram-negative bacteria, anaerobes, and fungi, making treatment complex.
Effective management of cIAIs involves a combination of broad-spectrum antibiotics and surgical intervention for source control. However, the rise of multidrug-resistant pathogens, such as ESBL-producing Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa, has increased the demand for novel treatment options. The Complicated Intra-Abdominal Infections market continues to evolve with advancements in antimicrobial therapies, improved diagnostic tools, and enhanced infection management strategies.
Get a Free sample for the Complicated Intra-Abdominal Infections Market Report: https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market
Complicated Intra-Abdominal Infections Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Complicated Intra-Abdominal Infections Epidemiology Segmentation:
The Complicated Intra-Abdominal Infections epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Total Incident Cases of IAI in the US
• Total Incident Cases of cIAI in the US
• Incident Cases of cIAI Based on Place of Acquisition in the US
• Gender-specific Incident Cases of cIAI in the US
• Type-specific Incident Cases of cIAI in the US
Download the report to understand which factors are driving Complicated Intra-Abdominal Infections epidemiology trends @ Complicated Intra-Abdominal Infections Epidemiology Forecast
Complicated Intra-Abdominal Infections Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Complicated Intra-Abdominal Infections market or expected to be launched during the study period. The analysis covers drug uptake in the market, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind their maximal use. Additionally, it compares the drugs based on market share.
The report also covers the Complicated Intra-Abdominal Infections Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Complicated Intra-Abdominal Infections Market Strengths
• The development of novel broad-spectrum antibiotics and combination therapies has improved treatment outcomes for drug-resistant infections.
• Increased awareness among healthcare professionals and advancements in rapid diagnostic techniques enhance early detection and timely intervention.
Complicated Intra-Abdominal Infections Market Weaknesses
• The emergence of multidrug-resistant pathogens, such as ESBL-producing Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa, limits treatment options.
• The financial burden of prolonged hospital stays, surgical interventions, and advanced antibiotic therapies makes treatment less accessible, particularly in low-income regions.
Scope of the Complicated Intra-Abdominal Infections Market Report
• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Complicated Intra-Abdominal Infections Companies: MerLion Pharmaceuticals, AiCuris, Novartis, Allecra, AbbVie, AstraZeneca, Pfizer, Shionogi, Iterum Therapeutics, Nosopharm, and others.
• Complicated Intra-Abdominal Infections Therapeutic Assessment: Complicated Intra-Abdominal Infections currently marketed and Complicated Intra-Abdominal Infections emerging therapies
• Complicated Intra-Abdominal Infections Market Dynamics: Complicated Intra-Abdominal Infections market drivers and Complicated Intra-Abdominal Infections market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Complicated Intra-Abdominal Infections Unmet Needs, KOL’s views, Analyst’s views, Complicated Intra-Abdominal Infections Market Access and Reimbursement
To learn more about the key players and advancements in the Complicated Intra-Abdominal Infections Treatment Landscape, visit the Complicated Intra-Abdominal Infections Market Analysis Report
Table of Contents
1. Complicated Intra-Abdominal Infections Market Report Introduction
2. Executive Summary for Complicated Intra-Abdominal Infections
3. SWOT analysis of Complicated Intra-Abdominal Infections
4. Complicated Intra-Abdominal Infections Patient Share (%) Overview at a Glance
5. Complicated Intra-Abdominal Infections Market Overview at a Glance
6. Complicated Intra-Abdominal Infections Disease Background and Overview
7. Complicated Intra-Abdominal Infections Epidemiology and Patient Population
8. Country-Specific Patient Population of Complicated Intra-Abdominal Infections
9. Complicated Intra-Abdominal Infections Current Treatment and Medical Practices
10. Complicated Intra-Abdominal Infections Unmet Needs
11. Complicated Intra-Abdominal Infections Emerging Therapies
12. Complicated Intra-Abdominal Infections Market Outlook
13. Country-Wise Complicated Intra-Abdominal Infections Market Analysis (2019–2032)
14. Complicated Intra-Abdominal Infections Market Access and Reimbursement of Therapies
15. Complicated Intra-Abdominal Infections Market Drivers
16. Complicated Intra-Abdominal Infections Market Barriers
17. Complicated Intra-Abdominal Infections Appendix
18. Complicated Intra-Abdominal Infections Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Jatin VimalEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
